Cargando…

Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers

OBJECTIVE: The aim of this study was to summarise the pharmacokinetic findings from eight phase I studies in healthy volunteers given oral AZD5069, a selective small-molecule CXCR2 antagonist. METHODS: 240 healthy volunteers across eight phase I studies received single (0.1–200 mg) or multiple once-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cullberg, Marie, Arfvidsson, Cecilia, Larsson, Bengt, Malmgren, Anna, Mitchell, Patrick, Wählby Hamrén, Ulrika, Wray, Heather
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2018
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995788/ https://www.ncbi.nlm.nih.gov/pubmed/29856004 http://dx.doi.org/10.1007/s40268-018-0236-x

Ejemplares similares

Safety, pharmacokinetics and pharmacodynamics of the selective glucocorticoid receptor modulator AZD7594, following inhalation in healthy Japanese volunteers
por: Prothon, Susanne, et al.
Publicado: (2019)

Navafenterol (AZD8871) in healthy volunteers: safety, tolerability and pharmacokinetics of multiple ascending doses of this novel inhaled, long-acting, dual-pharmacology bronchodilator, in two phase I, randomised, single-blind, placebo-controlled studies
por: Balaguer, Victor, et al.
Publicado: (2020)

Navafenterol (AZD8871) in patients with mild asthma: a randomised placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of this novel inhaled long-acting dual-pharmacology bronchodilator
por: Jimenez, Eulalia, et al.
Publicado: (2020)

Safety, Pharmacokinetics and Pharmacodynamics of the Selective Glucocorticoid Receptor Modulator Velsecorat (AZD7594) Following Inhalation in Healthy Volunteers
por: Prothon, Susanne, et al.
Publicado: (2022)

Efficacy and safety of AZD7594, an inhaled non-steroidal selective glucocorticoid receptor modulator, in patients with asthma: a phase 2a randomized, double blind, placebo-controlled crossover trial
por: Brown, Mary N., et al.
Publicado: (2019)

Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator
por: Singh, Dave, et al.
Publicado: (2020)

Association of SNP rs5069 in APOA1 with Benign Breast Diseases in a Mexican Population
por: Domínguez-Díaz, Carolina, et al.
Publicado: (2022)

Inhibition of LPS-induced airway neutrophilic inflammation in healthy volunteers with an oral CXCR2 antagonist
por: Leaker, Brian R, et al.
Publicado: (2013)

Phase 1 Pharmacokinetic Study of AZD5718 in Healthy Volunteers: Effects of Coadministration With Rosuvastatin, Formulation and Food on Oral Bioavailability
por: Ericsson, Hans, et al.
Publicado: (2019)

High-level expression of a novel thermostable and mannose-tolerant β-mannosidase from Thermotoga thermarum DSM 5069 in Escherichia coli
por: Shi, Hao, et al.
Publicado: (2013)

A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK
por: Dean, Emma, et al.
Publicado: (2018)

Longitudinal FEV(1) and Exacerbation Risk in COPD: Quantifying the Association Using Joint Modelling
por: Zhudenkov, Kirill, et al.
Publicado: (2021)

The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756) − a selective CXCR2 antagonist − in healthy adult subjects
por: Miller, Bruce E., et al.
Publicado: (2015)

Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors
por: O'Hara, Mark H., et al.
Publicado: (2020)

CXCR4 antagonists for treatment of breast cancer
por: Cortés, Javier, et al.
Publicado: (2018)

Safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in a randomized, placebo‐controlled, phase I study in healthy volunteers
por: Gan, Li‐Ming, et al.
Publicado: (2019)

Dapagliflozin Pharmacokinetics Is Similar in Adults With Type 1 and Type 2 Diabetes Mellitus
por: Melin, Johanna, et al.
Publicado: (2022)

Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers—results of a dose escalation trial
por: Karpova, Darja, et al.
Publicado: (2017)

It’s Never over until It’s over: How Can Age and Ovarian Reserve Be Mathematically Bound through the Measurement of Serum AMH—A Study of 5069 Romanian Women
por: Doroftei, Bogdan, et al.
Publicado: (2015)

CXCR4 or CXCR7 antagonists treat endometriosis by reducing bone marrow cell trafficking
por: Pluchino, Nicola, et al.
Publicado: (2020)

Evaluation of Tolerability, Pharmacokinetics and Pharmacodynamics of Vicagrel, a Novel P2Y12 Antagonist, in Healthy Chinese Volunteers
por: Li, Xiaojiao, et al.
Publicado: (2018)

Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma
por: Naing, A, et al.
Publicado: (2012)

Evaluation of the Pharmacokinetic Interaction between Lesogaberan (AZD3355) and Esomeprazole in Healthy Subjects
por: Niazi, Mohammad, et al.
Publicado: (2012)

1934. Nirsevimab is Associated with Higher and More Sustained RSV Neutralizing Antibody Responses Compared with Standard of Care Palivizumab: Observations from a 2:1 Randomized, Phase 2/3 Trial in Medically Vulnerable Children (MEDLEY)
por: Wilkins, Deidre, et al.
Publicado: (2023)

Pharmacokinetics of Oral Taurine in Healthy Volunteers
por: Ghandforoush-Sattari, Mohammadreza, et al.
Publicado: (2010)

Pharmacokinetics of chloroquine and primaquine in healthy volunteers
por: Daher, André, et al.
Publicado: (2022)

Pharmacokinetics of intranasal amiloride in healthy volunteers
por: Yellepeddi, Venkata K., et al.
Publicado: (2023)

Targeting of CXCR4 by the Naturally Occurring CXCR4 Antagonist EPI-X4 in Waldenström’s Macroglobulinemia
por: Kaiser, Lisa Marie, et al.
Publicado: (2021)

Importance of Polymorphisms in the Gene of Paraoxonase-1 (SNP rs662) and Apolipoprotein A-I (SNP rs670 and rs5069) in Non-Smoking and Smoking Healthy Subjects and Patients with Acute Pancreatitis
por: Ściskalska, Milena, et al.
Publicado: (2022)

Phase 1 Studies to Define the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of the Nonsteroidal Mineralocorticoid Receptor Antagonist Apararenone in Healthy Volunteers
por: Nakamura, Tadakatsu, et al.
Publicado: (2020)

Effect of eight days bed rest on the incretin effect in healthy volunteers
por: Nielsen, ST, et al.
Publicado: (2015)

Two Phase II randomized trials on the CRTh2 antagonist AZD1981 in adults with asthma
por: Kuna, Piotr, et al.
Publicado: (2016)

CCR5 and CXCR4 antagonist and agonist binding sites
por: Teintze, Martin, et al.
Publicado: (2006)

Molecular basis for the antagonistic activity of an anti-CXCR4 antibody
por: Peng, Li, et al.
Publicado: (2015)

Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants
por: Wilkins, Deidre, et al.
Publicado: (2023)

Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers
por: Pithavala, Yazdi K., et al.
Publicado: (2010)

Population pharmacokinetics of olprinone in healthy male volunteers
por: Kunisawa, Takayuki, et al.
Publicado: (2014)

Pharmacokinetics of oral and intravenous melatonin in healthy volunteers
por: Andersen, Lars P. H., et al.
Publicado: (2016)

Study of GABA in Healthy Volunteers: Pharmacokinetics and Pharmacodynamics
por: Li, Junfeng, et al.
Publicado: (2015)

Pharmacokinetics of Cromolyn and Ibuprofen in Healthy Elderly Volunteers
por: Brazier, David, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_98mceu5neqjos0iq1fig05cmtj